The Body Covers: The 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy Coverage
The 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy
September 14, 2000
Then Joan Lo presented data from a small clinical trial with seven patients with evidence of lipodystrophy. They were treated with 3 mg a day of growth hormone (a dose between the huge doses used in wasting syndrome and the more "physiologic" doses). The group also checked insulin sensitivity, oral glucose tolerance, and body composition (DEXA) at baseline, month one and month six. In spite of the fact that persons with diabetes and elevated triglycerides were excluded from the study, one subject had to quit at week three due to hyperglycemia. Five people completed six months of HGH, with a dose reduction to 1.5 mg in one patient at month two for arthralgias. All five people experienced a reduction in hump size and/or abdominal girth. The lean body mass increased (the muscles) but, unfortunately, the patients continued to loose subcutaneous fat. These results are quite preliminary and we need well-designed randomized trials before recommending the use of growth hormone for this indication.
This article was provided by The Body PRO. Copyright © Body Health Resources Corporation. All rights reserved.